The total number of records retrieved from this search are 12. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_402	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration0.4 MOI	In-vitro result110% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_404	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration1 MOI	In-vitro result118% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_406	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration4 MOI	In-vitro result98% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_408	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration11 MOI	In-vitro result78% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_410	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration33 MOI	In-vitro result30% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_412	Virus nameAdenovirus	Virus strainCRAd-IL24 (Ad5/3Δ24cmvIL24)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with IL-24 gene incorporated in place of the deleted E3B region (ΔE3B) under transcriptional control of the human CMV promoter (CMVp).	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-24 gene incorporated in place of the deleted E3B region	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration100 MOI	In-vitro result18% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_426	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration0.4 MOI	In-vitro result110% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_428	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration1 MOI	In-vitro result130% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_430	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration4 MOI	In-vitro result116% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_432	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration11 MOI	In-vitro result100% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_434	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration33 MOI	In-vitro result50% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517
IDOV_436	Virus nameAdenovirus	Virus strainCRAd-ING4 (Ad5/3Δ24cmvING4)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutanat with CMVp-driven Inhibitor of Growth 4 (ING4) gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman cervical squamous cell carcinoma cell line	Cell lineOV-4	Concentration of cell line3.0E+5 to 5.0E+5 cells per well	In-vitro toxicityToxic to normal ovarian surface epithelial IOSE-120 and IOSE-523 cells	AssayMTS-based Cell Proliferation Assay (Promega)	In-vitro virus concentration100 MOI	In-vitro result16% cancer cell viability (percentages are calculated with respect to mock-infected cell monolayers)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27349517